Merck receives positive CHMP opinion for DELSTRIGO™ and PIFELTRO™ (doravirine) in the EU
Merck announced the CHMP of the EMA has adopted a positive opinion recommending granting of marketing authorization for two HIV-1 medicines: DELSTRIGO™; and PIFELTRO™ to be administered in combination with other antiretroviral medicines. DELSTRIGO and PIFELTRO. September 20, 2018